Complement Therapeutics Receives FDA Fast Track Designation for CTx001 for Geographic Atrophy Secondary to AMD

The FDA has granted Fast Track designation to CTx001 for treating Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an experimental AAV-based gene therapy that aims to regulate several pathways in the complement system CTx001 previously obtained FDA IND clearance and will be assessed in Opti-GAIN, a first-in-human Phase…

AstronauTx Names Veteran Biotech Leader Adam Rosenberg as Board Chair

Veteran executive with broad board-level experience at biotechnology firms in the US and Europe Provides significant operational, strategic, and deal-making knowledge as AstronauTx moves forward its novel pipeline aimed at enhancing sleep architecture to address neurodegenerative conditions LONDON, Jan. 7, 2026 — AstronauTx Ltd (“AstronauTx”), a biotech firm creating treatments…